Top 9 Companies in the Global Immunotherapy Drugs Market in 2024

The global immunotherapy drugs market was valued at USD 222.08 billion in 2023. The market is expected to grow at a CAGR of 11.20% during the forecast period of 2024-2032, with the values likely to reach USD 577.42 billion by 2032. The market is driven by advancements in cancer research and the growing adoption of targeted therapies across the globe.

Immunotherapy drugs are those that utilize the body's immune system to combat diseases, especially cancer. Such drugs work either by enhancing the immune system or aiding it in recognizing and combating the cancer cells. The drug categories include checkpoint inhibitors, monoclonal antibodies, cytokine therapies, and cancer vaccines. Immunotherapy has transformed cancer treatment as it provides targeted, less invasive alternatives to conventional treatments such as chemotherapy with long-lasting effects and better outcomes for patients.

The immunotherapy drugs market is experiencing tremendous growth with the enhancement in technology in cancer research and the quick adoption of targeted therapies. The increasing incidence of cancer, investment in research and development, and growing application areas of immunotherapy beyond cancer are other major factors that are aiding the expansion of the immunotherapy drugs market.

In September 2024, the collaboration between Insilico Medicine and Inimmune announced a collaboration that is poised to fuel innovation in the global immunotherapy drugs market. Utilizing AI platforms like Chemistry42, the partnership focuses on developing small-molecule immunotherapy drugs for cancer. This collaboration streamlines the drug discovery process, improving efficiency and accelerating the development of new treatments to address unmet medical needs.

Let’s explore the profile of top companies leading the global immunotherapy drugs market in 2024.

1.    AbbVie Inc.

AbbVie is one of the leading firms in the market, leading with treatments that leverage the power of the immune system in the fight against autoimmune and inflammatory diseases. With innovative therapies Rinvoq and Skyrizi designed to address critical conditions such as rheumatoid arthritis and psoriasis, AbbVie continues to advance immunotherapy and strengthen its position as a leader in the healthcare space.

2.    Amgen Inc.

Amgen is a prominent market leader, with its innovative, FDA-approved drug, Blinatumomab. This Bispecific T-cell Engager (BiTE) immunotherapy is used to treat acute lymphoblastic leukemia by targeting the immune cells of the human body and engaging them in the killing of cancerous cells. Blinatumomab shows the potential of immunotherapy in oncology, representing an innovative approach to a new generation of treatments for hard-to-treat cancers.

3.    AstraZeneca PLC

AstraZeneca is one of the most significant players in the global market for immunotherapy drugs. It has a strong oncology focus, with the portfolio comprising advanced immuno-oncology therapies that use the immune system of the body to target cancer cells. AstraZeneca's innovative drugs are designed to transform the treatment of different cancers. It has an ever-growing pipeline of next-generation immunotherapy drugs to address unmet medical needs.

4.    Bristol-Myers Squibb

Bristol Myers Squibb (BMS) is a leader in the global immunotherapy drugs market. The company has developed leading-edge therapies that harness the power of the immune system to fight cancer. Subcutaneous immunotherapy is an area where BMS aims to improve access and outcomes in oncology. Its innovative drugs are changing the face of cancer treatment and providing new hope for better patient outcomes.

5.    F. Hoffmann-La Roche AG

Roche plays a major role in the market, concentrating on innovative cancer treatments that harness the immune system to target and eliminate cancer cells. Leveraging advanced technology, Roche's immunotherapy drugs aim to improve outcomes for patients with various cancer types, solidifying its leadership in oncology-focused immunotherapy.

6.    GlaxoSmithKline PLC.

GSK is one of the global immunotherapy drug leaders. It focuses more on creating innovative treatments that will address cancer. The company’s research explores the potential of combining its investigational drugs with other immunotherapies, such as Merck's Keytruda, to enhance the immune system's ability to fight cancer more effectively.

7.    Johnson & Johnson Services, Inc.

Johnson & Johnson is a leading company in the global immunotherapy drugs market with innovative treatments such as Carvykti, also known as ciltacabtagene autoleucel. FDA-approved Carvykti is a BCMA-directed CAR-T immunotherapy. It is intended to treat relapsed or refractory multiple myeloma. Such approvals have marked J&J's commitment to advancing cell therapies, thereby expanding cancer treatment options through a whole spectrum of immunotherapy drugs.

8.    Merck & Co. Inc.

Merck & Co. is the leader in immunotherapy drugs, especially with a pioneering immuno-oncology drug known as Keytruda (pembrolizumab). The latter has revolutionized cancer treatment by boosting immune response to tumors. In their focus on immunotherapy drugs, they have also been influencing cancer treatment protocols, through innovation and improving the outcomes for patients suffering from different types of cancers.

9.    Boehringer Ingelheim GmbH

Boehringer Ingelheim is a leader in the global immunotherapy drugs market and has been exploring immune-oncology medicines. Its approach focuses on targeting immune checkpoints such as SIRP-α, thereby boosting the body's immune response towards cancer. The immunotherapy drug pipeline at Boehringer Ingelheim might bring an end to cancer by providing patients with new and potent therapeutic choices.